Skip to main content
PortfolioRapha Capital Management

AXT107 Restores Healthy, Non-Leaky Vasculature in the Eye by Inhibiting VEGFR2 and Activating Tie2, the Two Clinically Validated Pathways in Diseases of the Retina

By March 18, 2019February 4th, 2021No Comments

AsclepiX Therapeutics
AXT107 Restores Healthy, Non-Leaky Vasculature in the Eye by Inhibiting VEGFR2 and Activating Tie2, the Two Clinically Validated Pathways in Diseases of the Retina

  • AXT107 exhibited a dual mechanism of action as a monotherapy, disrupting a key component of the Vascular Endothelial Growth Factor (VEGF) signaling pathway while also activating the Tie2 pathway that is integral to maintenance of vascular homeostasis.
  • A single monotherapy injection of AXT107 demonstrated in vivo efficacy lasting for many months, suggesting patients may require only 1 to 2 injections per year.
  • To date, AXT107 has demonstrated excellent safety, superior efficacy and longer durability in in vivo models compared to current standard of care treatments.
March 18, 2019